TL;DR: Aetna, a CVS Health company, modified CPB 0977 covering pertuzumab, trastuzumab, and hyaluronidase-zzxf (Phesgo), effective September 26, 2025. Billing teams need to confirm precertification workflows and charge capture for HCPCS J9316 are current before claims go out.
This update to the Aetna Phesgo coverage policy touches every oncology and infusion practice billing Phesgo to commercial Aetna plans. The primary billing code is HCPCS J9316 — injection, pertuzumab, trastuzumab, and hyaluronidase-zzxf, per 10 mg — alongside CPT 96401 for the subcutaneous administration. ICD-10 diagnosis codes C50.011 through C50.929 cover the malignant neoplasm of breast diagnoses that anchor medical necessity. If your practice treats HER2-positive breast cancer patients on Aetna commercial plans, this policy governs your reimbursement.
Quick-Reference Table
| Field | Detail |
|---|---|
| Payer | Aetna, a CVS Health company |
| Policy | Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf (Phesgo) |
| Policy Code | CPB 0977 |
| Change Type | Modified |
| Effective Date | September 26, 2025 |
| Impact Level | High |
| Specialties Affected | Medical Oncology, Hematology/Oncology, Infusion Therapy, Specialty Pharmacy |
| Key Action | Confirm precertification is active before billing J9316 on any Aetna commercial claim |
Aetna Phesgo Coverage Criteria and Medical Necessity Requirements 2025
The CPB 0977 Aetna system coverage policy is explicit on one point: precertification is required. No exceptions for participating providers or members in applicable plan designs. Before you administer Phesgo and before you bill J9316, you need an approved prior authorization on file.
The diagnosis anchor for medical necessity is malignant neoplasm of breast — ICD-10 codes C50.011 through C50.929. That range covers right, left, bilateral, and unspecified breast malignancy across all anatomical sub-sites. Phesgo is a HER2-targeted combination agent. Your clinical team already knows the indication. Your billing team needs to know that the ICD-10 codes on the claim must fall within this range, or the claim will fail medical necessity screening on the front end.
For Medicare criteria, this policy explicitly points elsewhere. CPB 0977 governs commercial medical plans only. If you're billing Medicare, Aetna directs you to the separate Medicare Part B criteria. Keep those two pathways clean in your billing system — mixing commercial and Medicare criteria is a fast way to generate claim denial volume.
The prior authorization phone number is (866) 752-7021. The fax line is (888) 267-3277. For Statement of Medical Necessity forms, Aetna routes you to their Specialty Pharmacy Precertification page. Make sure your prior auth team has these contacts saved — not just in someone's email, but in your actual workflow documentation.
One thing this policy does not spell out in the CPB 0977 summary is the specific clinical selection criteria Aetna applies when reviewing precertification requests. That's not unusual for a modified CPB — the criteria are embedded in the full policy document, which your billing and clinical teams need to pull directly from Aetna. Don't assume the prior auth will auto-approve based on diagnosis code alone. Reimbursement depends on the clinical criteria being met and documented in the request.
Coverage Indications at a Glance
| Indication | Status | Relevant Codes | Notes |
|---|---|---|---|
| Malignant neoplasm of breast (all sub-sites) | Covered when selection criteria are met | J9316, CPT 96401, C50.011–C50.929 | Precertification required; commercial plans only |
| Medicare beneficiaries on Aetna Medicare plans | See Medicare Part B Criteria (separate) | — | CPB 0977 does not govern Medicare — use Aetna's Medicare Part B pathway |
Aetna Phesgo Billing Guidelines and Action Items 2025
Phesgo billing is straightforward when the precertification is in place. It gets expensive fast when it isn't. Here are the concrete steps your team needs to take before and after the effective date of September 26, 2025.
| # | Action Item |
|---|---|
| 1 | Audit your open Aetna commercial prior authorizations for Phesgo. Pull every active patient on Phesgo who has Aetna commercial coverage. Confirm the prior auth is current, covers the correct date of service range, and was obtained under CPB 0977. If any authorization predates the modified policy, call (866) 752-7021 to confirm it remains valid. |
| 2 | Update your charge capture for J9316 with the correct unit reporting. HCPCS J9316 is billed per 10 mg. Phesgo comes in a fixed-dose combination — pertuzumab 1,200 mg / trastuzumab 600 mg / hyaluronidase-zzxf 30,000 units per vial. Calculate your units carefully. Under-billing costs you reimbursement. Over-billing creates a claim denial and a potential compliance issue. |
| 3 | Pair J9316 with CPT 96401 for the administration component. Subcutaneous chemotherapy administration bills under CPT 96401. These two codes work together on the claim. If your charge capture only captures J9316 and drops the administration code, you're leaving money on the table every visit. |
| 4 | Confirm ICD-10 coding lands in the C50.011–C50.929 range. All breast malignancy sub-sites fall in this range, but coders sometimes use unspecified codes that drift outside it. Specificity matters here. Your ICD-10 code needs to match the tumor location documented in the clinical record. |
| 5 | Separate your commercial and Medicare billing workflows for Phesgo. CPB 0977 covers commercial plans only. If you have patients on Aetna Medicare Advantage, their coverage criteria are governed by the Medicare Part B pathway, not this CPB. Mixing these is a common source of prior auth mismatches and denials. Build a hard separation into your workflow. |
| 6 | Pull the full CPB 0977 document for the complete clinical selection criteria. The policy summary confirms precertification is required and that coverage applies when "selection criteria are met." The full clinical criteria are in the complete policy document. Your prior auth team and your compliance officer need to review those criteria before the effective date. If you're not sure how this applies to your patient mix, talk to your compliance officer before September 26, 2025. |
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for Phesgo Under CPB 0977
Covered HCPCS Codes (When Selection Criteria Are Met)
| Code | Type | Description |
|---|---|---|
| J9316 | HCPCS | Injection, pertuzumab, trastuzumab, and hyaluronidase-zzxf, per 10 mg |
Other CPT Codes Related to CPB 0977
| Code | Type | Description |
|---|---|---|
| 96401 | CPT | Chemotherapy administration, subcutaneous or intramuscular; non-hormonal anti-neoplastic |
Note on CPT 96401: Aetna lists this code as "other CPT codes related to the CPB" — not in the covered codes group. That language signals it's relevant to the service but may be subject to separate coverage review or facility vs. professional billing rules depending on your setting. If your practice bills in a hospital outpatient setting, your facility fee billing guidelines govern how 96401 is handled. Confirm with your compliance officer how this code is treated under your specific contract.
Key ICD-10-CM Diagnosis Codes
| Code Range | Description |
|---|---|
| C50.011–C50.929 | Malignant neoplasm of breast (all sub-sites, laterality, and histology variations within this range) |
The C50 range is broad, but it's not unlimited. Codes outside C50.011–C50.929 — including metastatic breast cancer coded to the metastatic site rather than the breast primary — need to be reviewed for policy alignment. Document your primary site carefully.
A Note on What This Policy Doesn't Tell You
CPB 0977 is a precertification-required policy. That's clear. What it doesn't publish in the summary is the specific clinical criteria Aetna uses to approve or deny those precertification requests. This is the real issue for billing teams dealing with Phesgo prior auth.
Oncology practices billing Phesgo to Aetna commercial plans deal with high-cost drug claims. J9316 units add up fast on a drug with a per-vial price in the thousands. A single denied claim can represent significant revenue at risk.
That means the prior auth request has to be right the first time. Your clinical staff needs the full CPB 0977 to know what Aetna is reviewing — HER2 status documentation, staging, prior therapy history, and any step therapy requirements Aetna may apply. The billing team and the clinical team need to be aligned before the auth goes in.
If your practice is newer to billing Phesgo under Aetna commercial plans, the September 26, 2025 effective date is the right trigger to run a full workflow review. Don't wait for a denial to find the gap.
Get the Full Picture for CPT 96401
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.